Seedchrony evaluates uterine readiness for embryo implantation through the use of uterine biomarkers and the patient’s clinical parameters. The measurement is carried out non-invasively, without the need for tissue biopsies or fluid aspiration, takes only two minutes, and delivers immediate results.
The medical device has already achieved highly promising results in a pilot trial involving 80 in vitro fertilization patients, conducted in collaboration with the Vall d’Hebron University Hospital Foundation – Research Institute (VHIR).
A team led by Ramon Manyà advised Manina Medtech on this transaction. RCD had previously also advised the start-up on its first investment round.
cloud technology axon
This pioneering initiative is designed to support both organic and ino...
Capital-Riesgo.es
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Capital-Riesgo.es - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory
